share_log

Allogene Therapeutics Announces Patient Screening Underway For Pivotal Phase 2 ALPHA3 Trial At Rocky Mountain Cancer Centers, Astera Cancer Care, And Norton Cancer Institute; ALPHA3 To Offer CAR T As First Line Treatment At Community Cancer Centers,...

Benzinga ·  Jul 1 08:31

Allogene Therapeutics Announces Patient Screening Underway For Pivotal Phase 2 ALPHA3 Trial At Rocky Mountain Cancer Centers, Astera Cancer Care, And Norton Cancer Institute; ALPHA3 To Offer CAR T As First Line Treatment At Community Cancer Centers, Aiming To Complete Enrollment By 1H 2026 And Potential BLA Submission In 2027

  • Patient Screening is Underway at Rocky Mountain Cancer Centers, Part of the US Oncology Network and Sarah Cannon Research Institute; Astera Cancer Care, Part of the OneOncology Network; and Norton Cancer Institute
  • ALPHA3 Will be the First Pivotal Trial to Offer CAR T as Part of First Line (1L) Treatment at Community Cancer Centers, Where 80% of Patients Receive Care
  • ALPHA3 Expected to Complete Enrollment in 1H 2026; Potential BLA Submission in 2027
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment